Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

McKesson needs FTC wholesaler merger decision before AmeriSource March opt-out date.

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

McKESSON NEEDS FTC DECISION ON WHOLESALER MERGERS BEFORE MARCH 31 to retain the number one position in the wholesaler market through a merger with AmeriSource. By reaching an agreement shortly after the Cardinal Health/Bergen Brunswig deal was announced, McKesson may have hoped to ensure that the mergers receive joint review by the Federal Trade Commission. In that case, either an approval or a rejection by FTC would ensure that McKesson remains number one.

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

EU Launches Critical Medicines Alliance But Prospect Of Act On Manufacturing Still Uncertain

‘Shocking’ MHRA Performance & Poor Data Transparency Blamed For UK’s Clinical Trial Crisis

Updated COVID-19 Vaccines Should Target New JN.1 Variant, Says EMA

EMA Pilots Partnering With Companies To Gain Efficiencies In Preparing Drug Assessment Reports

See All
UsernamePublicRestriction

Register

PS088162

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By